Vaxart Stock Is Moving Higher After The Bell: What's Going On?
Vaxart Stock Is Moving Higher After The Bell: What's Going On?
Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday's after-hours session after the company provided business and cash runway updates.
Vaxart Inc（納斯達克：VXRT）股票在週一的盤後交易中上漲，因爲公司提供了業務和現金淨流量更新。
What Happened: Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.
Vaxart，一家臨床生物技術公司，正在開發一系列口服重組生物-疫苗。該公司在週一宣佈，最近一輪融資所籌集的資金以及其獲得的Project NextGen獎項補償款將延長其現金流量的期限至2026年。
"The past week was especially important for Vaxart, because the combination of receiving one of the largest Project NextGen awards from BARDA and closing our $40 million financing from leading institutional investors significantly strengthened the Company," said Steven Lo, CEO of Vaxart.
"過去的一週對Vaxart特別重要，因爲我們既獲得了BARDA最大的Project NextGen獎項之一，又從領先機構投資者那裏完成了4000萬美元的融資，顯著增強了公司實力和生命力，" Vaxart的CEO Steven Lo說。
"These notable achievements enable us to pursue our goal of creating transformative oral pill vaccine candidates representing multibillion-dollar market opportunities and offering the world a better way to protect against disease."
"這些顯著的成就使我們能夠追求創造具有數十億美元市場機會的轉化性口服疫苗候選藥物，併爲世界提供更好的疾病防護方式。"
Vaxart said it plans to use funds from the award to conduct a 10,000-subject Phase 2b comparative study evaluating its oral pill COVID-19 vaccine candidate against an FDA-approved mRNA vaccine comparator. Vaxart noted it could initiate enrollment in the trial as early as the summer of 2024.
Vaxart表示，計劃利用獲得的資金進行一項10000名受試者的2b期比較研究，評估其口服新冠疫苗候選藥物與FDA批准的mRNA疫苗比較。 Vaxart指出，該公司可能最早在2024年夏季開始招募試驗對象。
Vaxart also announced that it remains on track to receive feedback from the FDA in mid-2024 on potential correlates of protection for norovirus. The company said it will then determine the best way to progress its norovirus program.
Vaxart還宣佈，該公司計劃在2024年中期收到FDA有關諾如病毒保護相關性檢驗的反饋。該公司表示，然後將確定推進其諾如病毒項目的最佳方法。
Vaxart noted it continues to develop earlier-stage programs, including seasonal influenza and human papillomavirus. The company said it has also begun efforts on avian flu in light of the recent bird flu outbreaks.
Vaxart指出，除了針對最近禽流感暴發採取的行動外，該公司還在繼續開發季節性流感和人乳頭瘤病毒等早期項目。
VXRT Price Action: At publication Monday, Vaxart shares were up 3.67% at 54 cents in after-hours trading, according to Benzinga Pro.
VXRT股價表現：根據Benzinga Pro的消息，在週一的盤後交易中，Vaxart股票上漲3.67％，報54美分。
譯文內容由第三人軟體翻譯。